Short Interest in Elekta AB (OTCMKTS:EKTAY) Declines By 45.6%

Elekta AB (OTCMKTS:EKTAYGet Free Report) was the recipient of a significant decrease in short interest in August. As of August 31st, there was short interest totaling 3,337 shares, a decrease of 45.6% from the August 15th total of 6,134 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average daily volume of 6,268 shares, the short-interest ratio is currently 0.5 days.

Elekta Trading Up 1.9%

OTCMKTS:EKTAY opened at $5.11 on Tuesday. The stock has a fifty day moving average price of $5.26 and a two-hundred day moving average price of $5.64. The stock has a market capitalization of $1.88 billion, a price-to-earnings ratio of -42.58 and a beta of 1.05. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.68 and a current ratio of 0.87. Elekta has a 1 year low of $4.35 and a 1 year high of $6.93.

Elekta (OTCMKTS:EKTAYGet Free Report) last issued its earnings results on Thursday, August 27th. The company reported $0.07 EPS for the quarter. The company had revenue of $372.30 million for the quarter. Elekta had a negative net margin of 2.38% and a positive return on equity of 13.31%. As a group, sell-side analysts anticipate that Elekta will post 0.43 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Zacks Research raised Elekta from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 28th. One analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, Elekta presently has an average rating of “Hold”.

Get Our Latest Analysis on Elekta

Elekta Company Profile

(Get Free Report)

Elekta AB is a Sweden-based medical technology company focused on radiation oncology and precision treatment solutions. The company develops and supplies systems used to diagnose, plan and deliver treatments for cancer and other conditions affecting the brain and nervous system.

Its product portfolio includes linear accelerators for external-beam radiotherapy, stereotactic radiosurgery systems such as Leksell Gamma Knife, brachytherapy equipment and treatment-planning, oncology information and workflow software.

Featured Stories

Receive News & Ratings for Elekta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elekta and related companies with MarketBeat.com's FREE daily email newsletter.